# US 8,771,686 B2 · Methods for treating a disease involving choroidal neovascularization by administering an IL-6 receptor antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,771,686 B2
- Document ID: US8771686B2
- Status: Granted
- Kind: B2
- Application number: 12/161,733
- Filed: 2007-01-26
- Published: 2010-02-11
- Granted: 2014-07-08
- Earliest claimed: 2006-01-27
- Assignees: Chugai Seiyaku Kabushiki Kaisha
- Applicants: Susumu Ishida
- Inventors: Susumu Ishida
- Web page: https://patentgrep.com/patent/US8771686B2

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/02: Ophthalmic agents
- A61K 2039/505: {comprising antibodies}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present inventors focused on the fact that inflammation at the subretinal macular area enhances choroidal neovascularization, and developed pharmaceutical agents that suppress initiation or advancement of neovascularization by angiogenic factors such as VEGF. More specifically, the present inventors revealed that administering anti-IL-6 receptor monoclonal antibodies to mice treated with laser photocoagulation inhibits the development of choroidal neovascularization.

## Claims

### Claim 1

A method for treating a disease involving choroidal neovascularization, the method comprising administering an interleukin-6 (IL-6) inhibitor to a subject identified as having developed a disease involving choroidal neovascularization, thereby treating the disease in the subject,
wherein the disease involving choroidal neovascularization is age-related macular degeneration, myopic choroidal neovascularization, or idiopathic choroidal neovascularization, and wherein the IL-6 inhibitor is an antibody that binds to an IL-6 receptor and inhibits signal transduction via the IL-6 receptor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the antibody is a monoclonal antibody.

### Claim 3 (depends on 1)

The method of claim 1, wherein the IL-6 receptor is a human IL-6 receptor.

### Claim 4 (depends on 1)

The method of claim 1, wherein the antibody is a recombinant antibody.

### Claim 5 (depends on 1)

The method of claim 1, wherein the antibody is a chimeric, humanized, or human antibody.

### Claim 6 (depends on 1)

The method of claim 1, wherein the disease involving choroidal neovascularization is age-related macular degeneration.

### Claim 7 (depends on 1)

The method of claim 1, wherein the disease involving choroidal neovascularization is myopic choroidal neovascularization.

### Claim 8 (depends on 1)

The method of claim 1, wherein the disease involving choroidal neovascularization is idiopathic choroidal neovascularization.

### Claim 9 (depends on 1)

The method of claim 1, wherein the antibody is a MR16-1 antibody.

### Claim 10 (depends on 1)

The method of claim 1, wherein the antibody is a PM-1 antibody.

### Claim 11 (depends on 1)

The method of claim 1, wherein the antibody is a humanized PM-1 antibody.